For the treatment or suppression of genital herpes in immunocompetent individuals and for the suppression of recurrent genital herpes in HIV infected individuals.
To reduce the risk of transmission of genital herpes with the use of suppressive therapy.
No clinically significant interactions have been identified. Screen drug specific interactions for interactions via CYP 1A2 and pharmacodynimc adverse effects.
Increased risk of nephrotoxicity when used concomitantly with other nephrotoxic agents.